GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Goodwill-to-Asset

Mereo BioPharma Group (Mereo BioPharma Group) Goodwill-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Mereo BioPharma Group's Goodwill for the quarter that ended in Dec. 2023 was $0.00 Mil. Mereo BioPharma Group's Total Assets for the quarter that ended in Dec. 2023 was $66.50 Mil. Therefore, Mereo BioPharma Group's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 was 0.00.


Mereo BioPharma Group Goodwill-to-Asset Historical Data

The historical data trend for Mereo BioPharma Group's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Goodwill-to-Asset Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only - - - - -

Mereo BioPharma Group Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mereo BioPharma Group's Goodwill-to-Asset

For the Biotechnology subindustry, Mereo BioPharma Group's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Goodwill-to-Asset falls into.



Mereo BioPharma Group Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Mereo BioPharma Group's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/66.499
=0.00

Mereo BioPharma Group's Goodwill to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Goodwill to Asset (Q: Dec. 2023 )=Goodwill/Total Assets
=0/66.499
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mereo BioPharma Group  (NAS:MREO) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Mereo BioPharma Group Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group (Mereo BioPharma Group) Headlines